Isolating Human Cardiac Ventricular Progenitor Cells via Dual Marker Selection
Solution Overview
Problem
Current methods face challenges in isolating and expanding human cardiac ventricular progenitor cells that predominantly differentiate into functional ventricular muscle cells, lacking suitable cell surface markers for efficient isolation and large-scale expansion, and struggling to form pure, functional 3D ventricular muscle tissue in vivo.
Innovation Solution
The use of negative selection of day 5-7 cardiac progenitor cells, specifically isolating human cardiac ventricular progenitor cells (HVPs) using markers like TRA-1-60, and subsequent positive selection with markers such as JAG1, FZD4, LIFR, FGFR3, and TNFSF9, to achieve a highly purified population that differentiates almost exclusively into ventricular muscle cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cell transplantation methods are used, then cardiac function improvement is attempted, but the ability to form pure, functional 3D ventricular muscle tissue is insufficient
Solution Approach 1:
The patent segments the cell population into distinct stages: undifferentiated hPSCs, cardiac progenitor cells (days 3-7), and mature cardiomyocytes (days 14-28). This temporal segmentation allows isolation of intermediate progenitor cells that possess both proliferative capacity and ventricular differentiation potential, resolving the contradiction between cell purity and functional capability
Solution Approach 2:
The patent performs preliminary differentiation of hPSCs into cardiac progenitor cells before transplantation, using specific culture conditions (Wnt inhibition, BMP activation) to pre-commit cells to the cardiac lineage. This preliminary action ensures that transplanted cells are already primed to form ventricular tissue, improving both reliability and manufacturing precision
2Productivity
If cell surface markers are used for isolation, then expansion efficiency is improved, but suitable markers for ventricular progenitor cells are lacking
Solution Approach 1:
The patent uses intermediate markers (Isl1, Nkx2.5, Mesp1) that are expressed during the transitional cardiac progenitor stage as mediators to identify and isolate ventricular-progenitor cells. These intermediary markers bridge the gap between undifferentiated state and mature cardiac phenotype, enabling efficient isolation without requiring terminal differentiation markers
Solution Approach 2:
The patent employs dynamic parameter changes in culture conditions (Wnt pathway modulation, growth factor addition) to induce transient expression of specific markers on cardiac progenitor cells. This temporal parameter control creates windows of marker expression that can be exploited for isolation, solving the marker availability problem
Data Source
AI summary
The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.